title: Rationale for hypothalamus-deep brain stimulation in food intake disorders and obesity.
abstract: Appetite modulation in conjunction with enhancing metabolic rate with hypothalamic lesions has been widely documented in animal and even in humans. It appears these effects can be reproduced by DBS, and the titratability and reversibility of this procedure, in addition to well established safety profile, make DBS an appealing option for obesity treatment. Targeting the hypothalamus with DBS has already been shown to be feasible and potentially effective in managing patients with intractable chronic cluster headache [26]. The surgical risk however must be cautiously taken into account when targeting the hypothalamus, where some mortality cases have been reported when targeting the posterior part [34]. The development of new surgical approach will probably reduce this surgical risk. Moreover, the role of functional neurosurgery in obesity is not a new idea. In fact, LH was targeted in obese humans with electrocoagulation more than 30 years ago, resulting in significant yet transient appetite suppression and slight weight reduction [36]. All those elements have made possible the recent regain of interest in DBS for morbid obesity and open an exciting new area of research in neurosurgery and endocrinology.
authors.affiliation: CEA CLINATEC, Grenoble, France.
authors.forename: N
authors.initials: N
authors.lastname: Torres
authors.forename: S
authors.initials: S
authors.lastname: Chabardès
authors.forename: A L
authors.initials: AL
authors.lastname: Benabid
mesh_terms: D000818:Animals; D001066:Appetite / Q000502:physiology; D046690:Deep Brain Stimulation / Q000379:methods* / Q000639:trends; D004435:Eating / Q000502:physiology*; D001068:Feeding and Eating Disorders / Q000503:physiopathology* / Q000628:therapy; D006801:Humans; D009767:Obesity, Morbid / Q000503:physiopathology* / Q000628:therapy; D051381:Rats; D014697:Ventromedial Hypothalamic Nucleus / Q000502:physiology*